Transfusion Medicine and Hemotherapy
Daratumumab for Pure Red Cell Aplasia After ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review of Efficacy and Safety
Par Abdulrahman Fadhl Al-Mashdali, Mujahid O Abdelraof, Mohamed Elfatih M Yousif et 4 autres.
Contenu en anglais
Résumé
Background
Pure red cell aplasia (PRCA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an uncommon complication, most often associated with major or bidirectional ABO incompatibility. Daratumumab has emerged as a plasma cell–targeted therapy, but the supporting evidence remains limited.